Al Yue Lin

US Patent:

7405274, Jul 29, 2008

Filed:

Jun 1, 2004

Appl. No.:

10/858186

Inventors:

Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Noelynn A. Oliver - Los Altos CA, US
William R. Usinger - Lafayette CA, US
Qingjian Wang - Belmont CA, US
David A. Yeowell - San Francisco CA, US

Assignee:

FibroGen, Inc. - South San Francisco CA

International Classification:

C12P 21/08
C07K 16/00

US Classification:

5303871, 5303873, 5303881, 53038823

Abstract:

The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

US Patent:

7618940, Nov 17, 2009

Filed:

Dec 4, 2003

Appl. No.:

10/729167

Inventors:

Patrick D. Fourney - Walnut Creek CA, US
Stephen J. Klaus - San Francisco CA, US
Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Todd W. Seeley - Moraga CA, US

Assignee:

FibroGen, Inc. - San Francisco CA

International Classification:

C12Q 1/37

US Classification:

514 3, 435 23

Abstract:

The present invention provides methods and compounds for regulating fat metabolism and achieving fat homoeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e. g. , obesity, diabetes, atherosclerosis, etc.

US Patent:

7871617, Jan 18, 2011

Filed:

Jun 9, 2008

Appl. No.:

12/157262

Inventors:

Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Noelynn A. Oliver - Los Altos CA, US
William R. Usinger - Lafayette CA, US
Qingjian Wang - Belmont CA, US
David A. Yeowell - San Francisco CA, US

Assignee:

FibroGen, Inc. - San Francisco CA

International Classification:

A61K 39/395
A61K 38/18

US Classification:

4241391, 4241411, 4241451, 4241581, 4241331, 5303873, 5303879, 5303881, 53038824, 530399

Abstract:

The present invention relates to antibodies that bind to a portion of the Von Willebrand's factor (VWC) domain of connective tissue growth factor (CTGF). The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.

US Patent:

8202834, Jun 19, 2012

Filed:

Oct 19, 2009

Appl. No.:

12/589229

Inventors:

Patrick D. Fourney - Walnut Creek CA, US
Stephen J. Klaus - Boston MA, US
Al Y. Lin - Castro Valley CA, US
Thomas B. Neff - Atherton CA, US
Todd W. Seeley - Oakland CA, US

Assignee:

FibroGen, Inc. - San Francisco CA

International Classification:

A61K 31/47

US Classification:

514 11, 514292, 514307, 514312, 514346, 435375

Abstract:

The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e. g. , obesity, diabetes, atherosclerosis, etc.

US Patent:

20030153503, Aug 14, 2003

Filed:

Dec 6, 2002

Appl. No.:

10/313643

Inventors:

Stephen Klaus - San Francisco CA, US
Al Lin - Castro Valley CA, US
Thomas Neff - Atherton CA, US
Qingjian Wang - Davis CA, US
Michael Arend - San Mateo CA, US
Lee Flippin - Woodside CA, US
Alex Melekhov - San Mateo CA, US

International Classification:

A61K038/17

US Classification:

514/012000

Abstract:

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

US Patent:

20060178316, Aug 10, 2006

Filed:

Apr 17, 2006

Appl. No.:

11/406023

Inventors:

Stephen Klaus - San Francisco CA, US
Al Lin - Castro Valley CA, US
Thomas Neff - Atherton CA, US
Qingjian Wang - Belmont CA, US
Michael Arend - Foster City CA, US
Lee Flippin - Woodside CA, US
Alex Melekhov - Irvine CA, US

Assignee:

FibroGen, Inc. - South San Francisco CA

International Classification:

A61K 31/47
A61K 38/04

US Classification:

514019000, 514310000

Abstract:

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

US Patent:

20060178317, Aug 10, 2006

Filed:

Apr 17, 2006

Appl. No.:

11/406484

Inventors:

Stephen Klaus - San Francisco CA, US
Al Lin - Castro Valley CA, US
Thomas Neff - Atherton CA, US
Qingjian Wang - Belmont CA, US
Michael Arend - Foster City CA, US
Lee Flippin - Woodside CA, US
Alex Melekhov - Irvine CA, US

Assignee:

FibroGen, Inc. - South San Francisco CA

International Classification:

A61K 38/04
A61K 31/4745

US Classification:

514019000, 514291000

Abstract:

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.

US Patent:

20060183695, Aug 17, 2006

Filed:

Apr 17, 2006

Appl. No.:

11/405734

Inventors:

Stephen Klaus - San Francisco CA, US
Al Lin - Castro Valley CA, US
Thomas Neff - Atherton CA, US
Qingjian Wang - Belmont CA, US
Michael Arend - Foster City CA, US
Lee Flippin - Woodside CA, US
Alex Melekhov - Irvine CA, US

Assignee:

FibroGen, Inc. - South San Francisco CA

International Classification:

A61K 38/04
A61K 31/502

US Classification:

514019000, 514248000

Abstract:

The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.